'Brexit' as a Frustrating Event and the Case of Canary Wharf v. European Medicine Agency

2020 ◽  
Author(s):  
Mitja Kovac ◽  
Paul Aubrecht
Keyword(s):  
European Medicine Agency ◽  
Canary Wharf

scholarly journals Dosis de refuerzo de vacuna SARS CoV-2 para la prevención de COVID-19: Desafío en un escenario con incertezas

2021 ◽  
Vol 36 (2) ◽  
Author(s):  
Dr. Eduardo Lopez Mora, Dr. Rodrigo Cruz ◽  
Dr. Jorge Espinoza ◽  
Dr. Jorge Espinoza ◽  
Dra. Jeannette Dabanch ◽  
Dra. Jeannette Dabanch ◽  
...  
Keyword(s):  
European Medicine Agency

Al 16 de julio pasado existían 108 vacunas en etapa clínica de desarrollo, 28 de ellas con estudios en fase III y 6 autorizadas por la Organización Mundial de la Salud (OMS) según datos publicados al 3 de junio (AstraZeneca/Oxford, Johnson and Johnson/Janssen, Moderna, Pfizer/BionTech, Sinopharm, Sinovac) (1,2).  A la vez, las entidades regulatorias como la FDA (Food and Drugs Agency) y la EMA (European Medicine Agency) han autorizado para uso de emergencia las vacunas de los productores Pfizer/BioNTech, Moderna, AstraZeneca y Janssen (3) y en Chile el Instituto de Salud Pública ha autorizado 6 vacunas (Pfizer, CoronaVac, Astrazeneca, CanSino, Janssen, Sputnik).En las últimas semanas, en el contexto de la preocupante propagación de la variante Delta (B.1.617.2) del SARS-CoV-2, la compañía Pfizer solicitó a la FDA la autorización para la administración de una dosis de refuerzo (booster) con su vacuna  BNT162b2 , luego de que el análisis interino de datos provenientes de la población vacunada en Israel mostrará una reducción significativa de los anticuerpos neutralizantes a los seis meses de completado el esquema primario, solicitud que generó debate en la comunidad científica.  Hasta ahora los datos disponibles sobre eficacia de la vacuna BNT162b2 en escenario de circulación de variantes sugieren que continúa siendo altamente efectiva (4,5). Los estudios para definir la eventual necesidad de una dosis de refuerzo a diferentes esquemas primarios están en etapas de reclutamiento inicial en varios países.

scholarly journals Stosowanie leków biopodobnych w hematoonkologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów

2019 ◽  
Vol 50 (2) ◽  
pp. 51-56
Author(s):  
Iwona Hus ◽  
Joanna Drozd-Sokołowska ◽  
Lidia Gil ◽  
Ewa Lech-Marańda ◽  
Krzysztof Giannopoulos ◽  
...  
Keyword(s):  
European Society ◽  
European Medicine Agency ◽  
Medical Oncology

StreszczenieLeki biopodobne odgrywają coraz większą rolę w terapii wielu chorób wraz z wygaśnięciem ochrony patentowej dla kolejnych leków biologicznych. Celem niniejszego opracowania jest przybliżenie terminologii i zasad wprowadzania na rynek leków biopodobnych, zagadnień dotyczących ich etykietowania, ekstrapolacji, wymienialności i automatycznej substytucji. Opracowanie to przedstawia stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów dotyczące leków biopodobnych, oparte na wytycznych EMA (European Medicine Agency) i stanowisku ESMO (European Society of Medical Oncology).

Canary Wharf: Financing and Placemaking

2017 ◽  
Author(s):  
William N. Goetzmann ◽  
Jean W. Rosenthal ◽  
Jaan Elias
Keyword(s):  
Canary Wharf

Suing in Tort for Loss of Computer Data

1999 ◽  
Vol 58 (1) ◽  
pp. 67-77
Author(s):  
C. A. R. Weston
Keyword(s):  
Economic Loss ◽  
Computer Hardware ◽  
Computer Data ◽  
Pure Economic Loss ◽  
Correct Analysis ◽  
Canary Wharf

DOES the loss of computer data constitute damage to property for the purposes of an action in negligence, or is it pure economic loss? On the test in Hunter v. Canary Wharf Ltd. [1997] A.C. 655, if the loss of data is concomitant with a change in the configuration in the particles of the computer hardware by means of which the data are stored, the Courts are likely to find that damage to property has taken place. This is likely to have significant implications in the context of problems caused by the “millennium bug”. However, whatever may be the correct analysis of the nature of the loss, de minimis principles and considerations of fairness, justice and reasonableness may militate against the imposition of liability in tort, at least where the loss of data is negligently, rather than deliberately, caused.

The Canary Wharf Debacle: From ‘TINA’—There is No Alternative—To ‘THEMBA’—There Must Be an Alternative

1993 ◽  
Vol 25 (9) ◽  
pp. 1247-1265 ◽  
Author(s):  
A Merrifield
Keyword(s):  
Economic Policy ◽  
Commercial Real Estate ◽  
The Political ◽  
Financial Asset ◽  
Short Term ◽  
Progressive Politics ◽  
The United Kingdom ◽  
Canary Wharf ◽  
Market Driven ◽  
London Docklands

In this paper, the recent failure of the Canary Wharf project at London Docklands in the wake of the financial collapse of Canadian property giant, Olympia and York, is critically examined. Some theoretical pointers are offered as to how the Canary Wharf affair arose, the logic through which it was implemented, and the political and financial mechanisms deployed to ride the storm are highlighted. The shifts occurring in the global political economy since the mid-1970s are charted, particularly the massive explosion of the financial sector. These developments have, in turn, rendered commercial real estate a pure financial asset. It is argued that it is this mechanism that spurred the frenetic speculation and overinvestment in the property sector throughout much of the 1980s. This was especially so at London Docklands as investment activities there were further catalysed by an urban and economic policy that endorsed market-driven, speculative short-term practices. The contradictions and instabilities this process engendered at Canary Wharf itself, and how the ensuing ‘fallout’ has been minimised and legitimated in the United Kingdom through effective nationalisation are examined. The paper is concluded with a discussion on the implications the débâcle has for critical theory and progressive politics.

Sign in / Sign up

Export Citation Format

Share Document